Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity

Oluwaseun Falade-Nwulia; Catherine R. Lesko; Anthony T. Fojo; Jeanne C. Keruly; Richard D. Moore; Catherine G. Sutcliffe; Shruti H. Mehta; Geetanjali Chander; David L. Thomas; Mark Sulkowski

doi:10.1093/infdis/jiad433

Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity

Oluwaseun Falade-Nwulia, Catherine R. Lesko, Anthony T. Fojo, Jeanne C. Keruly, Richard D. Moore, Catherine G. Sutcliffe, Shruti H. Mehta, Geetanjali Chander, David L. Thomas, Mark Sulkowski

Research output: Contribution to journal › Article › peer-review

Abstract

Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%–46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%–4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.

Original language	English (US)
Pages (from-to)	775-779
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	229
Issue number	3
DOIs	https://doi.org/10.1093/infdis/jiad433
State	Published - Mar 15 2024

Keywords

HIV
elimination
health equity
hepatitis C

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/jiad433

Cite this

@article{eb8c63b1625744af86352015f7193338,

title = "Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity",

abstract = "Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%–46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%–4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.",

keywords = "HIV, elimination, health equity, hepatitis C",

author = "Oluwaseun Falade-Nwulia and Lesko, {Catherine R.} and Fojo, {Anthony T.} and Keruly, {Jeanne C.} and Moore, {Richard D.} and Sutcliffe, {Catherine G.} and Mehta, {Shruti H.} and Geetanjali Chander and Thomas, {David L.} and Mark Sulkowski",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2024",

month = mar,

day = "15",

doi = "10.1093/infdis/jiad433",

language = "English (US)",

volume = "229",

pages = "775--779",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Hepatitis C Treatment in People With HIV

T2 - Potential to Eliminate Disease and Disparity

AU - Falade-Nwulia, Oluwaseun

AU - Lesko, Catherine R.

AU - Fojo, Anthony T.

AU - Keruly, Jeanne C.

AU - Moore, Richard D.

AU - Sutcliffe, Catherine G.

AU - Mehta, Shruti H.

AU - Chander, Geetanjali

AU - Thomas, David L.

AU - Sulkowski, Mark

N1 - Publisher Copyright: © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

PY - 2024/3/15

Y1 - 2024/3/15

N2 - Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%–46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%–4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.

AB - Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%–46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%–4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.

KW - HIV

KW - elimination

KW - health equity

KW - hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=85187925991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85187925991&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiad433

DO - 10.1093/infdis/jiad433

M3 - Article

C2 - 37793170

AN - SCOPUS:85187925991

SN - 0022-1899

VL - 229

SP - 775

EP - 779

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 3

ER -

Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this